Double blinded, vehicle controlled, crossover study on the efficacy of a topical endocannabinoid membrane transporter inhibitor in atopic Beagles

Marsella, Rosanna; Ahrens, Kim; Sanford, Rachel; Trujillo, Andrew D.; Massre, D; Soeberdt, Michael; Abels, Christoph

doi:10.1007/s00403-019-01963-4

Cited by 8 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have suggested that the antipruritic, lipostatic and anti-inflammatory effects of CBD-and PEA-containing products have therapeutic potential for inflammatory skin disorders such as atopic dermatitis and acne vulgaris. 2,3,[15][16][17][18][19][20][21] However, the findings extrapolated from our study can only support the tolerability of certain cannabinoid products among healthy participants with nondiseased skin.…”

Section: Discussionmentioning

confidence: 83%

“…The impact of topical cannabinoids on skin health and potential anti-inflammatory modulation of the immune system has become a focus of attention as insight into the pathological roles of endogenous cannabinoids has increased. [1][2][3] Although data from animal studies are promising, the safety and tolerability of topical cannabinoid-containing products remain largely unexplored in humans. 4 Cannabidiol (CBD) and hemp oils are extracted from the flowers and leaves of the Cannabis sativa (hemp) plant.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tolerability profile of topical cannabidiol and palmitoylethanolamide: a compilation of single‐centre randomized evaluator‐blinded clinical and in vitro studies in normal skin

Maghfour

Rietcheck

Szeto

et al. 2021

Clin Experimental Derm

View full text Add to dashboard Cite

Background. An increasing number of studies have investigated the adverse effect profile of oral cannabinoids; however, few studies have provided sufficient data on the tolerability of topical cannabinoids in human participants. Aim. To assess the tolerability profile of several commercial topical formulations containing cannabidiol (CBD) and palmitoylethanolamide (PEA) on the skin of healthy human participants. Methods. Three human clinical trials and one in vitro study were conducted. The potential for skin irritation, sensitization and phototoxicity of several products, were assessed via patch testing on healthy human skin. The products assessed included two formulations containing CBD and PEA, one containing hemp seed oil and four concentrations of CBD alone. Ocular toxicity was tested using a traditional hen's egg chorioallantoic membrane model with three CBD, PEA and hemp seed oil formulations.Results. There was no irritation or sensitization of the products evident via patch testing on healthy participants. Additionally, mild phototoxicity of a hemp seed oil product was found at the 48-h time point compared with the negative control. The in vitro experiment demonstrated comparable effects of cannabinoid products with historically nonirritating products. Conclusion. These specific formulations of CBD-and PEA-containing products are nonirritating and nonsensitizing in healthy adults, and further encourage similar research assessing their long-term safety and efficacy in human participants with dermatological diseases. There are some limitations to the study: (i) external validity may be limited as formulations from a single manufacturer were used for this study, while vast heterogeneity exists across unregulated, commercial CBD products on the market; and (ii) products were assessed only on normal, nondiseased human skin, and therefore extrapolation to those with dermatological diseases cannot be assumed.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Tolerability profile of topical cannabidiol and palmitoylethanolamide: a compilation of single‐centre randomized evaluator‐blinded clinical and in vitro studies in normal skin

Maghfour

Rietcheck

Szeto

et al. 2021

Clin Experimental Derm

View full text Add to dashboard Cite

show abstract

“…Beagles allergic to dust mites were tested for the influence of endocannabinoid membrane transporter inhibitor on pruritus and dermatitis. Increasing levels of endocannabinoids improved atopic dermatitis and caused pruritus to alleviate after dust mite provocation in the experimental group [ 65 ].…”

Section: Cannabinoids In Inflammatory Skin Diseasesmentioning

confidence: 99%

The Therapeutic Potential of Cannabis in Counteracting Oxidative Stress and Inflammation

2021

View full text Add to dashboard Cite

Significant growth of interest in cannabis (Cannabis sativa L.), especially its natural anti-inflammatory and antioxidative properties, has been observed recently. This narrative review aimed to present the state of the art of research concerning the anti-inflammatory activity of all classes of cannabinoids published in the last five years. Multimodal properties of cannabinoids include their involvement in immunological processes, anti-inflammatory, and antioxidative effects. Cannabinoids and non-cannabinoid compounds of cannabis proved their anti-inflammatory effects in numerous animal models. The research in humans is missing, and the results are unconvincing. Although preclinical evidence suggests cannabinoids are of value in treating chronic inflammatory diseases, the clinical evidence is scarce, and further well-designed clinical trials are essential to determine the prospects for using cannabinoids in inflammatory conditions.

show abstract

“…[130] Feasibility of this mode of action was shown in a canine model of AD: topical application of WOL067-531 reduced AD flares in dogs after allergen exposure with negligible penetration into the circulation. [130] In a murine model, WOL067-531 significantly delayed barrier repair and reduced SDS-induced inflammation. [128] In a mouse model of dermatitis, the N-acylethanolamine acid amidase (NAAA) inhibitor ARN077 was shown to suppress inflammation and pruritus.…”

Section: Endo C Annab Inoid Sys Tem (Ec S) Modul Ator Smentioning

confidence: 99%

“…WOL067‐531 inhibits endocannabinoid reuptake, with the aim of prolonging and elevating endocannabinoid concentrations outside of the cell and enhancing activation of cannabinoid receptors. [ 130 ] Feasibility of this mode of action was shown in a canine model of AD: topical application of WOL067‐531 reduced AD flares in dogs after allergen exposure with negligible penetration into the circulation. [ 130 ] In a murine model, WOL067‐531 significantly delayed barrier repair and reduced SDS‐induced inflammation.…”

Section: Endocannabinoid System (Ecs) Modulatorsmentioning

confidence: 99%

Current and emerging treatments targeting the neuroendocrine system for disorders of the skin and its appendages

Soeberdt

Kilić

Abels

2020

Experimental Dermatology

View full text Add to dashboard Cite

The skin as a neuroendocrine organ and the role of neuroendocrine signalling in the development of disorders affecting the skin and its appendages has received increasing attention in the last years. Different neuroendocrine systems have been described in the barrier organ skin, including the thyroid system, the hypothalamicpituitary-adrenal axis, the opioid, the endocannabinoid, the cholinergic, the secosteroidogenic and the serotonergic systems. All of these systems have been implicated in the development of skin diseases, which often have an inflammatory origin. These discoveries have led to an increase in the development of new drugs targeting components of neuroendocrine signalling pathways. Additionally, attempts have been made to repurpose already approved drugs targeting neuroendocrine signalling pathways in other organs for the treatment of skin diseases. Recently published results from preclinical and clinical studies look promising and may offer improved therapies to patients suffering from skin diseases in the near future. In this review, from a pharmaceutical point of view, we focus on recent progress in synthetic drug development of compounds targeting neuroendocrine signalling in the skin and its appendages to treat skin diseases such as atopic dermatitis, psoriasis, acne, alopecia areata and hyperhidrosis.

show abstract

Double blinded, vehicle controlled, crossover study on the efficacy of a topical endocannabinoid membrane transporter inhibitor in atopic Beagles

Cited by 8 publications

References 21 publications

Tolerability profile of topical cannabidiol and palmitoylethanolamide: a compilation of single‐centre randomized evaluator‐blinded clinical and in vitro studies in normal skin

Tolerability profile of topical cannabidiol and palmitoylethanolamide: a compilation of single‐centre randomized evaluator‐blinded clinical and in vitro studies in normal skin

The Therapeutic Potential of Cannabis in Counteracting Oxidative Stress and Inflammation

Current and emerging treatments targeting the neuroendocrine system for disorders of the skin and its appendages

Contact Info

Product

Resources

About